Citizens JMP Reiterates Buy Rating on Zevra Therapeutics (ZVRA), Keeps PT
Its fiscal Q1 2025 results, reported on May 15, showed positive operations, with net revenue reaching $20.4 million, driven by product net revenue of $17.2 million.
Zevra Therapeutics Inc. (ZVRA)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | AIGH Investment Partners Orin Hirschman | 918,893 | $8,095,448 | -37% | 3.64% |
| 2. | Altium Capital Jacob Gottlieb | 0 | $0 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $7.84 | 300 | $2,351.52 | 1,800 | 2025-03-28 | Filing | |
| $7.96 | 10,000 | $79,624.00 | 40,000 | 2025-03-19 | Filing | |
| $7.92 | 500 | $3,957.65 | 1,500 | 2024-10-11 | Filing | |
| $6.77 | 2,000 | $13,540.00 | 18,469 | 2024-07-17 | Filing | |
| $6.81 | 10,000 | $68,065.00 | 20,000 | 2024-07-16 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $9.21 | 24,000 | $221,004.00 | 42,666 | 2025-06-26 | Filing | |
| $7.86 | 3,000 | $23,587.80 | 16,341 | 2025-02-13 | Filing | |
| $7.86 | 10,500 | $82,526.85 | 29,486 | 2025-02-13 | Filing | |
| $7.86 | 11,000 | $86,471.00 | 51,361 | 2025-02-13 | Filing | |
| $8.05 | 30,544 | $245,961.67 | 191,516 | 2025-02-14 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 4,081,544 | $35,958,402 | 0% | |
| 2. | 2,952,686 | $26,013,163 | 0% | |
| 3. | 1,242,386 | $10,947,721 | 0% | |
| 4. | 935,677 | $8,243,315 | 0% | |
| 5. | 553,297 | $4,874,547 | 2.17% |
News See All
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Q1 2025 Earnings Call Transcript
Operator: Good afternoon and thank you for joining Zevra's First Quarter 2025 Financial Results and Corporate Update Conference Call.
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Q4 2024 Earnings Call Transcript
Operator: Good afternoon, and thank you for joining Zevra's Therapeutics Fourth Quarter and Full Year 2024 Financial Results and Corporate Update Conference Call.
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Q3 2024 Earnings Call Transcript
Operator: Good afternoon, and thank you for joining Zevra Therapeutics Third Quarter Financial Results and Corporate Update Conference Call.
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Q2 2024 Earnings Call Transcript
Operator: Hello, and thank you for joining the Zevra Therapeutics Q2 2024 Financial Results and Corporate Highlights Call.
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Q1 2024 Earnings Call Transcript
Operator: Good morning, everyone. Thank you for joining the Zevra Therapeutics' First Quarter 2024 Corporate Update and Financial Results Call.
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Q4 2023 Earnings Call Transcript
Zevra Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-0.4 EPS, expectations were $-0.2.
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Q3 2023 Earnings Call Transcript
Operator: Good morning, everyone. Thank you for joining the Zevra Therapeutics Third Quarter 2023 Corporate Updates and Financial Results Call.
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Q2 2023 Earnings Call Transcript
Operator: Good morning, and welcome to the Zevra Therapeutics Second Quarter 2023 Corporate and Financial Results Conference Call.